tiprankstipranks
Trending News
More News >
S2Medical AB Class B (SE:S2M)
:S2M

S2Medical AB Class B (S2M) AI Stock Analysis

Compare
0 Followers

Top Page

SE

S2Medical AB Class B

(Frankfurt:S2M)

Rating:61Neutral
Price Target:
S2Medical AB Class B demonstrates strong financial performance with significant revenue and profit growth, positive cash flow, and a stable balance sheet. However, technical indicators show moderate momentum, and the negative P/E ratio raises valuation concerns. The overall score reflects a promising financial outlook but tempered by valuation and historical volatility risks.

S2Medical AB Class B (S2M) vs. iShares MSCI Sweden ETF (EWD)

S2Medical AB Class B Business Overview & Revenue Model

Company DescriptionS2Medical AB Class B (S2M) is a Swedish medical technology company specializing in the development and commercialization of advanced wound care products. The company operates within the healthcare sector, focusing on innovative solutions for wound healing and tissue regeneration. Its core products include a range of patented wound care technologies designed to improve healing outcomes and reduce the risk of infections.
How the Company Makes MoneyS2Medical AB generates revenue primarily through the sale of its advanced wound care products to hospitals, clinics, and other healthcare providers. The company's revenue model is based on direct sales, as well as partnerships and distribution agreements with medical distributors and healthcare organizations across various regions. Significant factors contributing to its earnings include the efficacy of its patented technologies, ongoing research and development efforts, and strategic collaborations with healthcare providers to expand product reach and adoption in different markets.

S2Medical AB Class B Financial Statement Overview

Summary
S2Medical AB Class B has shown strong revenue growth of 113.9% and improved profit margins. The balance sheet is stable with zero debt and a strong equity position. Cash flow management is robust, with positive free cash flow. However, historical volatility and a modest asset base present potential risks.
Income Statement
70
Positive
S2Medical AB Class B has shown a significant improvement in its financial performance over the past year. The company reported a substantial increase in total revenue from SEK 6.97 million in 2023 to SEK 14.91 million in 2024, reflecting a revenue growth rate of 113.9%. Gross profit margin is strong at 94.9%, indicating effective cost management. The net profit margin turned positive at 38.7% in 2024, compared to a negative margin in previous years, showing a successful turnaround. EBITDA margin has improved significantly to 45.8%. However, the historical volatility in earnings and previous losses suggest potential risks.
Balance Sheet
65
Positive
The company's balance sheet reflects a strong equity position with a total debt of zero and stockholders' equity amounting to SEK 11.8 million in 2024. The equity ratio is 65.2%, indicating financial stability and low leverage. Return on equity (ROE) has improved to 48.9%, demonstrating efficient use of equity capital. While the absence of debt is a positive indicator, the relatively modest asset base may limit growth opportunities compared to industry peers with larger asset pools.
Cash Flow
75
Positive
S2Medical AB Class B has demonstrated robust cash flow management. The free cash flow turned positive at SEK 2.49 million in 2024, reflecting significant improvement from previous negative figures. The operating cash flow to net income ratio is favorable at 0.54, indicating efficient cash conversion from profits. Additionally, the free cash flow to net income ratio suggests strong cash generation relative to earnings. The positive cash flow trajectory is a promising sign for sustaining future operations and investments.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue10.57M14.91M6.97M4.67M7.70M25.62M
Gross Profit-2.78M14.14M5.04M5.17M7.10M10.05M
EBITDA3.92M6.82M-13.53M-26.37M-18.73M-14.14M
Net Income-2.15M5.77M-22.71M-31.22M-20.32M-15.08M
Balance Sheet
Total Assets17.62M18.09M21.41M25.29M29.68M41.24M
Cash, Cash Equivalents and Short-Term Investments1.37M1.00M1.52M3.72M9.48M25.14M
Total Debt0.000.000.000.00207.69K830.77K
Total Liabilities7.48M6.29M19.75M18.22M15.00M8.48M
Stockholders Equity10.14M11.80M1.66M7.07M14.68M32.77M
Cash Flow
Free Cash Flow13.31M2.49M-17.67M-30.03M-22.76M-14.73M
Operating Cash Flow14.45M3.12M-16.52M-28.13M-19.67M-12.75M
Investing Cash Flow-1.14M-634.00K-1.15M-1.76M-3.02M-1.98M
Financing Cash Flow-13.60M3.79M15.47M24.14M6.85M24.41M

S2Medical AB Class B Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.01
Price Trends
50DMA
0.02
Negative
100DMA
0.01
Positive
200DMA
0.02
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
44.09
Neutral
STOCH
83.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:S2M, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.09 is Neutral, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:S2M.

S2Medical AB Class B Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
SES2M
61
Neutral
€11.40M
96.10%94.79%
51
Neutral
kr5.56B11.18-74.16%8.44%28.10%22.23%
47
Neutral
kr81.88M-79.12%86.02%93.34%
47
Neutral
kr81.88M-79.12%86.02%93.34%
46
Neutral
kr367.52M-88.97%-0.61%54.19%
34
Underperform
€68.48M
33
Underperform
kr62.17M
-63.52%93.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:S2M
S2Medical AB Class B
0.01
-0.02
-62.50%
SE:ACARIX
Acarix AB
0.35
-0.12
-25.49%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
3.19
-2.59
-44.81%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
3.19
-2.59
-44.81%
SE:QLIFE
Qlife Holding AB
4.98
3.62
266.99%
SE:HEART
Scandinavian Real Heart AB
13.70
-20.00
-59.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025